Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Preventing aggregation of amyloid beta (Aβ) peptides is a promising strategy for the
treatment of Alzheimer's disease (AD), and gold nanoparticles have previously been …

Due to the progressive aging of the population, Alzheimer's disease (AD) is becoming a
healthcare burden of epidemic proportions for which there is currently no cure …

Alzheimer's disease (AD), a common neurodegenerative disease in the elderly and the most
prevalent cause of dementia, is characterized by progressive cognitive impairment. The …

Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and
dementia, and affects 10–15% of the population over the age of 65. The failure of drug trials …

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD)
considering the disease as a continuum. Thanks to evolving biomarker research and …

Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …

Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

Brain‐derived neurotrophic factor (BDNF) is a neurotrophin that is vital to the survival,
growth, and maintenance of neurons in key brain circuits involved in emotional and …